Heng W, Lim H, Tan K, Poh C
Pharm Res. 2023; 40(8):1999-2025.
PMID: 37344603
DOI: 10.1007/s11095-023-03540-x.
Bentes G, Lanzarini N, Guimaraes J, Heinemann M, Volotao E, da Silva A
Viruses. 2022; 14(9).
PMID: 36146801
PMC: 9502344.
DOI: 10.3390/v14091995.
Shivshankar P, Karmouty-Quintana H, Mills T, Doursout M, Wang Y, Czopik A
Inflammation. 2022; 45(4):1430-1449.
PMID: 35320469
PMC: 8940980.
DOI: 10.1007/s10753-022-01656-7.
Kim B, Guaregua V, Chen X, Zhao C, Yeow W, Berg N
Inflammation. 2021; 44(4):1426-1440.
PMID: 33566257
PMC: 7873671.
DOI: 10.1007/s10753-021-01427-w.
Li X, Berg N, Mills T, Zhang K, Eltzschig H, Yuan X
Front Immunol. 2021; 11:604944.
PMID: 33519814
PMC: 7840604.
DOI: 10.3389/fimmu.2020.604944.
Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.
Olivera S, Perez A, Falcon V, Urquiza D, Pichardo D, Martinez-Donato G
Arch Virol. 2020; 165(3):593-607.
PMID: 32016547
PMC: 7224087.
DOI: 10.1007/s00705-019-04464-x.
Progress in the development of virus-like particle vaccines against respiratory viruses.
Quan F, Basak S, Chu K, Kim S, Kang S
Expert Rev Vaccines. 2020; 19(1):11-24.
PMID: 31903811
PMC: 7103727.
DOI: 10.1080/14760584.2020.1711053.
Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus.
Kim K, Kwon Y, Lee Y, Kim M, Hwang H, Ko E
Vaccines (Basel). 2018; 6(4).
PMID: 30241300
PMC: 6313937.
DOI: 10.3390/vaccines6040066.
Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
Lee Y, Ko E, Lee Y, Kim K, Kim M, Lee Y
PLoS One. 2018; 13(1):e0190868.
PMID: 29324805
PMC: 5764335.
DOI: 10.1371/journal.pone.0190868.
Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.
Kim Y, Lee Y, Kim M, Lee Y, Kim K, Ko E
Front Immunol. 2017; 8:1730.
PMID: 29276514
PMC: 5727122.
DOI: 10.3389/fimmu.2017.01730.
Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines.
Lee Y, Kim M, Lee Y, Kim Y, Kang S
Immune Netw. 2015; 15(5):213-21.
PMID: 26557805
PMC: 4637342.
DOI: 10.4110/in.2015.15.5.213.
Single-Dose CpG Immunization Protects Against a Heterosubtypic Challenge and Generates Antigen-Specific Memory T Cells.
Vogel A, Brown D
Front Immunol. 2015; 6:327.
PMID: 26161083
PMC: 4479795.
DOI: 10.3389/fimmu.2015.00327.
Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?.
Jalilian B, Christiansen S, Einarsson H, Pirozyan M, Petersen E, Vorup-Jensen T
Mol Cell Ther. 2015; 1:2.
PMID: 26056568
PMC: 4448954.
Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen.
Ingrole R, Tao W, Tripathy J, Gill H
Nano Life. 2015; 4(2):1450004.
PMID: 25825595
PMC: 4376021.
DOI: 10.1142/s1793984414500044.
Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.
Chowdhury M, Li R, Kim J, Park M, Kim T, Pathinayake P
PLoS One. 2014; 9(4):e94051.
PMID: 24714362
PMC: 3979752.
DOI: 10.1371/journal.pone.0094051.
Immune responses to oral and IM administration of M2e-Hsp70 construct.
Assadian F, Nikbakht G, Niazi S, Khaltabadi R, Jahantigh M
Vet Res Commun. 2014; 38(2):157-63.
PMID: 24595641
DOI: 10.1007/s11259-014-9599-9.
Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.
Kim M, Lee Y, Ko E, Lee J, Kwon Y, Hwang H
Mol Ther. 2014; 22(7):1364-1374.
PMID: 24590045
PMC: 4089011.
DOI: 10.1038/mt.2014.33.
Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.
Chowdhury M, Seo S, Moon H, Talactac M, Kim J, Park M
Virol J. 2014; 11:21.
PMID: 24502341
PMC: 3923897.
DOI: 10.1186/1743-422X-11-21.
Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.
Wang L, Hess A, Chang T, Wang Y, Champion J, Compans R
Nanomedicine. 2013; 10(2):473-82.
PMID: 23988715
PMC: 3948190.
DOI: 10.1016/j.nano.2013.08.005.
Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.
Tao W, Ziemer K, Gill H
Nanomedicine (Lond). 2013; 9(2):237-51.
PMID: 23829488
PMC: 3958969.
DOI: 10.2217/nnm.13.58.